-
公开(公告)号：US11903993B2
公开(公告)日：2024-02-20
申请号：US18060523
申请日：2022-11-30
Applicant: MAIA Pharmaceuticals, Inc.
Inventor： Srikanth Sundaram
CPC classification number: A61K38/10 , A61K9/0019 , A61K38/58 , A61K47/02 , A61K47/10 , A61P7/02 , A61K47/12 , A61K47/183
Abstract: Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.
-
公开(公告)号：US11872261B2
公开(公告)日：2024-01-16
申请号：US17673361
申请日：2022-02-16
Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
Inventor： Alan T. Remaley , Scott M. Gordon
CPC classification number: A61K38/005 , A61K38/07 , A61K38/08 , A61K38/10 , A61K38/1767 , A61K38/58 , A61K47/545 , A61K47/60
Abstract: Described herein is the design and construction of a class of lipoprotein targeting protease inhibitors. Small peptides with protease inhibitor activity are conjugated to hydrophobic, lipoprotein targeting molecules using, for instance, amine reactive chemistry. Methods of use of the resultant lipoprotein targeting protease inhibitor (antiprotease) molecules are also described. Also described is the production and use of protease inhibitor enriched HDL particles, as well as A1AT-peptide-enriched HDL particles, and their use in various therapeutic contexts.
-
公开(公告)号：US20170360944A1
公开(公告)日：2017-12-21
申请号：US15641679
申请日：2017-07-05
Applicant: Transdermal Biotechnology, Inc.
Inventor： Nicholas V. Perricone
IPC: A61K47/54 , A61K47/14 , A61K47/10 , A61K38/58 , A61K38/43 , A61K38/12 , A61K38/08 , A61K38/06 , A61K33/00 , A61K31/519 , A61K9/06 , A61K47/24 , A61K9/00
CPC classification number: A61K47/548 , A61K9/0014 , A61K9/06 , A61K31/519 , A61K33/00 , A61K38/066 , A61K38/08 , A61K38/12 , A61K38/43 , A61K38/58 , A61K47/10 , A61K47/14 , A61K47/24 , A61K2300/00
Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
-
公开(公告)号：US09775890B2
公开(公告)日：2017-10-03
申请号：US14374730
申请日：2012-06-15
Applicant: Xavier Stephenne , Etienne Sokal , Mustapha Najimi , Stéphane Eeckhoudt , Cédric Hermans
Inventor： Xavier Stephenne , Etienne Sokal , Mustapha Najimi , Stéphane Eeckhoudt , Cédric Hermans
IPC: C12N5/00 , A61K38/58 , A61K45/06 , A61K31/5377 , A61K35/28 , A61K35/407
CPC classification number: A61K38/58 , A61K31/5377 , A61K35/28 , A61K35/407 , A61K45/06 , A61K2300/00
Abstract: The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one factor Xa inhibitor, preferably rivaroxaban, as well as at least one thrombin inhibitor, preferably bivalirudin.
-
公开(公告)号：US09757467B2
公开(公告)日：2017-09-12
申请号：US15041311
申请日：2016-02-11
Applicant: Transdermal Biotechnology, Inc.
Inventor： Nicholas V. Perricone
IPC: A61K9/127 , A61K9/06 , A61K31/519 , A61K38/06 , A61K47/24 , A61K47/10 , A61K47/48 , A61K9/00 , A61K33/00 , A61K38/08 , A61K38/12 , A61K38/43 , A61K47/14 , A61K38/58
CPC classification number: A61K47/548 , A61K9/0014 , A61K9/06 , A61K31/519 , A61K33/00 , A61K38/066 , A61K38/08 , A61K38/12 , A61K38/43 , A61K38/58 , A61K47/10 , A61K47/14 , A61K47/24 , A61K2300/00
Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
-
Patent Agency Ranking
公开(公告)号：US20170042940A1
公开(公告)日：2017-02-16
申请号：US15287061
申请日：2016-10-06
Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAIN
Inventor： Xavier Stephenne , Etienne Sokal , Mustapha Najimi , Stéphane Eeckhoudt , Cédric Hermans
IPC: A61K35/28 , A61K38/58 , A61K38/55 , A61K45/06 , A61K31/727
CPC classification number: A61K35/28 , A61K31/5377 , A61K31/727 , A61K31/737 , A61K35/407 , A61K38/55 , A61K38/58 , A61K45/06 , A61K2300/00
Abstract: The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one antithrombin activator, preferably unfractionated heparin, as well as at least one thrombin inhibitor, preferably bivalirudin.
Abstract translation: 本发明涉及细胞移植的组合物和方法。 特别地，本发明提供包含促凝血细胞和至少一种抗凝血酶活化剂，优选未分级肝素的组合物，以及至少一种凝血酶抑制剂，优选比伐卢定。
-
公开(公告)号：US20160158372A1
公开(公告)日：2016-06-09
申请号：US15041311
申请日：2016-02-11
Applicant: Transdermal Biotechnology, Inc.
Inventor： Nicholas V. Perricone
CPC classification number: A61K47/548 , A61K9/0014 , A61K9/06 , A61K31/519 , A61K33/00 , A61K38/066 , A61K38/08 , A61K38/12 , A61K38/43 , A61K38/58 , A61K47/10 , A61K47/14 , A61K47/24 , A61K2300/00
Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
Abstract translation: 本发明一般涉及用于治疗患有或具有动脉硬化，高血压，镰状细胞性贫血或其它病症风险的受试者的组合物和方法。 在一些情况下，组合物可以包括一氧化氮，肽或两者。 一氧化氮和/或肽可以存在于包含卵磷脂（例如磷脂酰胆碱）的第一相内。 在某些实施方案中，卵磷脂存在于含有一氧化氮和/或肽的脂质体，胶束或其它囊泡中。 组合物可以采用可以被摩擦或喷到皮肤上的凝胶，乳膏，洗剂，软膏，溶液，固体“棒”等的形式。 本发明的其它方面一般涉及制备或使用这种组合物的方法，促进这种组合物的方法，包括这种组合物的试剂盒等。
-
公开(公告)号：US20150266935A1
公开(公告)日：2015-09-24
申请号：US14431060
申请日：2013-09-27
Applicant: University of British Columbia
Inventor： Yu Tian Wang , Shelly Xuelai Lan , Wuyang Jin Jin
CPC classification number: C07K14/47 , A61K31/00 , A61K31/37 , A61K31/4365 , A61K38/00 , A61K38/1709 , A61K38/482 , A61K38/4886 , A61K38/58 , A61K45/06 , C07K2319/06 , C07K2319/10 , C07K2319/70 , C07K2319/95 , C12N9/12 , C12Y207/11001 , C12Y304/21 , C12Y304/21031 , C12Y304/21068 , C12Y304/24029 , A61K2300/00
Abstract: In one aspect, the invention provides a peptide comprising a chaperone-mediated autophagy (CMA)-targeting signal domain; a protein-binding domain that selectively binds to a target cytosolic protein; and a cell membrane penetrating domain (CMPD). In another aspect, the invention provides methods for reducing the intracellular expression level of an endogenous target protein in vitro and in an animal, wherein the method involves administration of the peptide. Methods are also provided for treating a pathological condition in an animal, the methods comprising administering the peptide to the animal. In one embodiment, the pathological condition is a neurodegenerative disease. In another embodiment of the invention, the target cytosolic protein is death associated protein kinase 1 and the CMPD is protein transduction domain of the HIV-1 Tat protein.
Abstract translation: 一方面，本发明提供了包含伴侣介导的自噬（CMA） - 靶向信号结构域的肽; 选择性结合靶细胞溶质蛋白的蛋白质结合结构域; 和细胞膜穿透结构域（CMPD）。 另一方面，本发明提供在体外和动物中降低内源性靶蛋白的细胞内表达水平的方法，其中该方法包括给予该肽。 还提供了用于治疗动物病理状况的方法，所述方法包括向动物施用肽。 在一个实施方案中，病理状况是神经变性疾病。 在本发明的另一个实施方案中，靶细胞溶质蛋白是死亡相关蛋白激酶1，并且CMPD是HIV-1 Tat蛋白的蛋白质转导结构域。
-
9.发明申请Treatment Of Diabetic Patients With A Drug Eluting Stent And Adjunctive Therapy 有权治疗糖尿病患者药物洗脱支架和辅助治疗公开(公告)号：US20130224255A1
公开(公告)日：2013-08-29
申请号：US13403709
申请日：2012-02-23
Applicant: Syed F.A. Hossainy , Paul M. Consigny
Inventor： Syed F.A. Hossainy , Paul M. Consigny
IPC: A61F2/82 , A61K31/426 , A61K31/4709 , A61K31/4365 , A61K31/519 , A61P7/00 , A61K31/573 , A61K31/565 , A61K38/44 , A61K31/45 , A61K31/506 , A61K31/553 , A61K31/65 , A61K31/436
CPC classification number: A61K38/28 , A61F2/82 , A61F2250/0067 , A61K31/426 , A61K31/436 , A61K31/4365 , A61K31/45 , A61K31/4709 , A61K31/506 , A61K31/519 , A61K31/553 , A61K31/565 , A61K31/573 , A61K31/65 , A61K35/58 , A61K38/58 , A61K45/06 , A61K2300/00
Abstract: Embodiments of the present invention include methods for the treatment, prevention, or amelioration of vascular disease in diabetic patients. The methods include both implantation of a stent including a first drug. Some embodiments include additional therapy, such as the co-administration of another drug. Some embodiments involve different stent selection for a diabetic patient compared to a non-diabetic patient.
Abstract translation: 本发明的实施方案包括用于治疗，预防或改善糖尿病患者血管疾病的方法。 所述方法包括植入包括第一药物的支架。 一些实施方案包括另外的治疗，例如另一种药物的共同给药。 与非糖尿病患者相比，一些实施方案涉及糖尿病患者的不同支架选择。
-
公开(公告)号：US20110020272A1
公开(公告)日：2011-01-27
申请号：US12843650
申请日：2010-07-26
Applicant: Ulrich SCHUBERT
Inventor： Ulrich SCHUBERT
IPC: A61K38/20 , A61K38/21 , A61K31/56 , A61K38/45 , A61K38/16 , A61K31/7056 , A61K31/708 , A61K31/353 , A61K31/407 , A61K31/426 , A61P31/14
CPC classification number: A61K38/20 , A61K31/69 , A61K31/7056 , A61K38/04 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/13 , A61K38/16 , A61K38/212 , A61K38/58 , A61K2300/00
Abstract: Disclosed are methods of using proteasome inhibitors (PI) in combinations with other pharmaceutically active agents for treating viral hepatitis infections, for example, for treating therapy-resistant and -refractory viral hepatitis infections. Also disclosed are pharmaceutical compositions and kits of pharmaceutical compositions which can be used for treating viral hepatitis infections, for example, for treating therapy-resistant and refractory viral hepatitis infections.
Abstract translation: 公开的是使用蛋白酶体抑制剂（PI）与其它药物活性剂组合用于治疗病毒性肝炎感染的方法，例如用于治疗耐药性和耐药性病毒性肝炎感染。 还公开了药物组合物和可用于治疗病毒性肝炎感染的药物组合物试剂盒，例如用于治疗耐药性和难治性病毒性肝炎感染。
-
-
-
-
-
-
-
-
-
Search Results
139
records
(took 0.056 seconds)
